Vivani Medical, an emerging biopharmaceutical company in the metabolic diseases space, is developing subdermal implants that are changed once or twice per year, delivering GLP-1R agonist with no ...

Vivani Medical, an emerging biopharmaceutical company in the metabolic diseases space, is developing subdermal implants that are changed once or twice per year, delivering GLP-1R agonist with no need ...

On March 26, 2025, Vivani announced promising preclinical data for NPM-139, its subdermal semaglutide implant that is under development for chronic weight management in obese and overweight ...

On March 26, 2025, Vivani announced promising preclinical data for NPM-139, its subdermal semaglutide implant that is under development for chronic weight management in obese and overweight ...

However, many rumors of Musk helping people have also been debunked. Recently, a post circulating online claimed that Elon Musk paid medical bills and arranged a Neuralink brain implant for a ...

The annual Grindfest meetup sees biohackers display implants and augmentations. As magician and biohacker Anastasia Synn approaches her home, she tries to open the front door and finds it locked.

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...

Vivani’s lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals. Vivani’s emerging ...